Employees: 1,961
Size HeiLongJiang ZBD Pharmaceutical (603567.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $610M, the 3201st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.42 on 18 Nov 2026.
Performance Over six months the shares fell 39.3%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue fell 82.0% over the last twelve months (peer median +4.6%).
Valuation It trades at 5.4× forward earnings against a peer median of 11.4× (cheapest of 6).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -25%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥286M | CN¥796M | CN¥2.69B | CN¥3.13B | CN¥4.20B |
| Revenue growth | — | -70% | -14% | -26% | — |
| Gross profit | n/a | -CN¥71.4M | CN¥1.40B | CN¥1.24B | CN¥639M |
| EBITDA | n/a | -CN¥1.31B | CN¥774M | CN¥303M | -CN¥108M |
| Net income | -CN¥1.48B | -CN¥1.37B | CN¥438M | CN¥473M | CN¥185M |
| Free cash flow | CN¥198M | CN¥254M | -CN¥1.42M | -CN¥553M | -CN¥679M |
| Capital expenditure | CN¥30.1M | CN¥68.5M | CN¥189M | CN¥95.1M | CN¥404M |
| Total debt | CN¥3.14B | CN¥3.14B | CN¥3.36B | CN¥3.26B | CN¥3.05B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603567.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.8% | -10.2% | 9th lowest of 20 |
| 6-month return | -39.3% | -26.6% | 6th lowest of 20 |
| Distance from 52-week high | -62.9% | -41.0% | 3rd lowest of 20 |
| Revenue growth (TTM) | -82.0% | +4.6% | lowest of 15 |
| Forward P/E | 5.4× | 11.4× | cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | 9.1% | -0.6% | 5th most demanding of 10 |
| Growth delivered (Del g) | -25.1% | +2.1% | lowest of 10 |
| Hurdle (Req g minus delivered) | +34.2 pp | +8.1 pp | 2nd most demanding of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 5.4× | 9.1% | -25.1% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | n/a | 10.1% | +2.1% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | n/a | -1.0% | -17.9% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 11.4× | -6.6% | +5.4% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | n/a | 10.9% | -5.9% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 83.1× | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 10.2× | -8.7% | +8.8% |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | n/a | -0.6% | -1.6% |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | n/a | n/a | n/a |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 54.0× | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 6.7× | -6.2% | +6.5% |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | n/a | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | n/a | 50.4% | -12.3% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | n/a | n/a | n/a |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | n/a | 36.3% | +16.2% |